Mismatch Repair Deficiency clinical trials at UCSF

1 research study open to eligible people

Mismatch repair deficiency is when cells can't fix errors in DNA. UCSF is studying a treatment using RP1 alone and with another drug called nivolumab. These trials help understand how these treatments work in people with this condition.

Showing trials for

  • RP1 Monotherapy and RP1 in Combination With Nivolumab

    open to eligible people ages 18 years and up

    RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

    San Francisco, California and other locations

Our lead scientists for Mismatch Repair Deficiency research studies include .

Last updated: